Current status and future developments of rhEPO in clinical oncology


As described in this book, anemia is a major cause of symptoms in cancer patients and a factor that possibly worsens the outcome of cancer treatment. The therapeutic options available for anemia are allogeneic RBC transfusions or recombinant human erythropoietin (rhEPO). The question, therefore, is when to use which of these two therapeutic modalities and how to use rhEPO to achieve its maximum effect. Referring to the broad spectrum of topics extensively discussed in this book, this chapter will deal with some practical issues for the use of both RBC transfusions and rhEPO and addresses approaches that could optimize treatment with rhEPO. In addition, recent results indicating rhEPO as a multipotential cytokine with manifold effects not only on the hematopoietic system, but also on other organs and tissues, will be addressed, and potential implications of these effects in cancer patients will be discussed.


Recombinant Human Erythropoietin Nephrol Dial Transplant Intravenous Iron Iron Sucrose Iron Dextran 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abayomi OK (1996) Pathogenesis of irradiation-induced cognitive dysfunction. Acta Oncol 35: 659–663PubMedCrossRefGoogle Scholar
  2. 2.
    Adamson JW (1994) The relationship of erythropoietin and iron metabolism to red blood cell production in humans. Semin Oncol 21 (Suppl 3): 9–15PubMedGoogle Scholar
  3. 3.
    Adamson JW, Cavill I, Fishbane S, Petersen J, Wish JB (1999) A consensus on current issues and controversies in iron management of patients with chronic renal failure. Seminars in Dialysis 12: 182–194CrossRefGoogle Scholar
  4. 4.
    Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20: 485–493PubMedCrossRefGoogle Scholar
  5. 5.
    Ahsan N (2000) Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Adv Perit Dial 16: 80–84PubMedGoogle Scholar
  6. 6.
    Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R (1982) Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1: 652–655PubMedCrossRefGoogle Scholar
  7. 7.
    Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N (2001) Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 37 (Suppl 6): S144 (abstract)CrossRefGoogle Scholar
  8. 8.
    Arcasoy MO, Amin K, Haroon ZA (2001) Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing. Blood 98: 822aGoogle Scholar
  9. 9.
    Auerbach M, Barker L, Bahrain H, Trout R, Mcllwain M, Ballard H (2001) Intravenous iron (IV Fe) optimizes the response to erythropietin (EPO) in patients with anemia of cancer and cancer chemotherapy: results of a multi 9 center, open-label, randomized trial. Blood 98: 799a (Abstr 3323)Google Scholar
  10. 10.
    Aul C, Gattermann N, Jaeger M (1997) [Therapy of transfusion hemochromatosis]. Internist (Berl) 38: 865–866Google Scholar
  11. 11.
    Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, Jaudon MC, Bourbouze R, Jacobs C, Deray G (2001) Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 16: 932–938PubMedCrossRefGoogle Scholar
  12. 12.
    Bailie GR, Johnson CA, Mason NA (2000) Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 35: 1–12PubMedCrossRefGoogle Scholar
  13. 13.
    Ballard H, Rana J, Ackerman A, et al (1999) Total dose infusion (TDI) of iron dextran (ID) optimizes erythropoietin (EPO) responsiveness in the anemia of cancer (CA). Proc Am Soc Clin Oncol 18: 581a (Abstr 2245)Google Scholar
  14. 14.
    Barrett-Lee PJ, Bailey NP, O’Brien ME, Wager E (2000) Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82: 93–97PubMedCrossRefGoogle Scholar
  15. 15.
    Battaglia A, Fattorossi A, Pierelli L, Bonanno G, Marone M, Ranelletti FO, Coscarella A, De Santis R, Bach S, Mancuso S, Scambia G (2000) The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/ erythropoietin) acts as a potent inducer of erythropoiesis. Exp Hematol 28: 490–498PubMedCrossRefGoogle Scholar
  16. 16.
    Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M, Dunst J (2000) Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 46: 459–466PubMedCrossRefGoogle Scholar
  17. 17.
    Beguin Y (1998) Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 25 (Suppl 7): 27–34PubMedGoogle Scholar
  18. 18.
    Beguin Y, Loo M, R’Zik S, Sautois B, Lejeune F, Rorive G, Fillet G (1993) Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82: 2010–2016PubMedGoogle Scholar
  19. 19.
    Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19: 643–651PubMedCrossRefGoogle Scholar
  20. 20.
    Bernell P, Stenke L, Wallvik J, Hippe E, Hast R (1996) A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in inyelodysplastic syndromes. Leuk Res 20: 693–699PubMedCrossRefGoogle Scholar
  21. 21.
    Besarab A (2000) Physiological and pharmacodynamic considerations for route of EPO administration. Semin Nephrol 20: 364–374PubMedGoogle Scholar
  22. 22.
    Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530–538PubMedGoogle Scholar
  23. 23.
    Birgegard G, Sandhagen B (2001) Erythropoetin treatment can increase 2,3diphosphoglycerate levels in red blood cells. Scand J Clin Lab Invest 61: 337–340PubMedCrossRefGoogle Scholar
  24. 24.
    Birmingham DJ, Shen XP, Hartman JA, Dillon JJ, Hebert LA (1996) Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Kidney Int 50: 543–549PubMedCrossRefGoogle Scholar
  25. 25.
    Bohl D, Heard JM (2000) Delivering erythropoietin through genetically engineered cells. J Am Soc Nephrol 11 Suppl 16: 5159–162Google Scholar
  26. 26.
    Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G (1998) Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Haematologica 83: 788–790PubMedGoogle Scholar
  27. 27.
    Bothwell TH, Bradlow BA, Jacobs P, Keeley K, Kramer S, Seftel H, Zail S (1964) Iron metabolism in scurvy with special reference to erythropoiesis. Br J Haematol 10: 50–58PubMedCrossRefGoogle Scholar
  28. 28.
    Bothwell TH (1968) The control of iron absorption. Br J Haematol 14: 453–456PubMedCrossRefGoogle Scholar
  29. 29.
    Bourantas KL, Tsiara S, Makis A, Chaidos A, Christou L, Konstantinidou P, Kolios G, Seferiadis K (1997) Recombinant human erythropoietin for the treatment of anemia in chronic myelogenous leukemia. Eur J Haematol 59: 263–265PubMedCrossRefGoogle Scholar
  30. 30.
    Bowen DT, Hellstrom-Lindberg E (2001) Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy? Leuk Res 25: 19–21PubMedCrossRefGoogle Scholar
  31. 31.
    Braga M, Gianotti L, Gentilini O, Vignali A, Corizia L, Di Carlo V (1999) Erythropoiesis after therapy with recombinant human erythropoietin: a dose-response study in anemic cancer surgery patients. Vox Sang 76: 38–42PubMedCrossRefGoogle Scholar
  32. 32.
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18: 2695–2701PubMedGoogle Scholar
  33. 33.
    Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97: 10526–10531PubMedCrossRefGoogle Scholar
  34. 34.
    Brugnara C (1998) Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res 28: 1–11PubMedCrossRefGoogle Scholar
  35. 35.
    Bunworasate U, Arnouk H, Minderman H, O’Loughlin KL, Sait SN, Barcos M, Stewart CC, Baer MR (2001) Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 98: 3492–3494PubMedCrossRefGoogle Scholar
  36. 36.
    Burns DL, Pomposelli JJ (1999) Toxicity of parenteral iron dextran therapy. Kidney Int Suppl 69: S119–124PubMedCrossRefGoogle Scholar
  37. 37.
    Casadevall N, Durieux P, Dubois S, et al (2001) Erythropoietin (rHuEpo) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): results of a randomised trial with impact on quality of life and costs. Blood 98: 848aGoogle Scholar
  38. 38.
    Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058–1062PubMedGoogle Scholar
  39. 39.
    Cazzola M (1999) Haematopoietic growth factors in the treatment of myelodysplastic syndromes. Forum (Genova) 9: 49–57Google Scholar
  40. 40.
    Cazzola M (2000) Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. Int J Hematol 72: 134–138PubMedGoogle Scholar
  41. 41.
    Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E (1988) Natural history of idiopathic refractory sideroblastic anemia. Blood 71: 305–312PubMedGoogle Scholar
  42. 42.
    Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, et al (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86: 4446–4453PubMedGoogle Scholar
  43. 43.
    Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberato NL, Fregoni V, Nalli G, Barosi G, Ascari E (1992) Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 79: 29–37Google Scholar
  44. 44.
    Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y (1996) Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81: 434–441PubMedGoogle Scholar
  45. 45.
    Cerami A (2001) Beyond erythropoiesis: Novel applications for recombinant human erythropoietin. Semin Hematol 38 (Suppl 7): 33–39PubMedCrossRefGoogle Scholar
  46. 46.
    Cerami A, Brines ML, Ghezzi P, Cerami CT (2001) Effects of epoetin alfa on the central nervous system. Semin Oncol 28 (Suppl 8): 66–70PubMedCrossRefGoogle Scholar
  47. 47.
    Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA (2001) Changes in erythropoietin pharmacokinetics following busulfaninduced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 298: 820–824PubMedGoogle Scholar
  48. 48.
    Cheung W, Minton N, Gunawardena K (2001) Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 57: 411–418PubMedCrossRefGoogle Scholar
  49. 49.
    Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC (1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64: 412–423PubMedCrossRefGoogle Scholar
  50. 50.
    Chin K, Yu X, Beleslin-Cokic B, Liu C, Shen K, Mohrenweiser HW, Noguchi CT (2000) Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res 81: 29–42PubMedCrossRefGoogle Scholar
  51. 51.
    Christensson AG, Danielson BG, Lethagen SR (2001) Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis. Nephrol Dial Transplant 16: 313–319PubMedCrossRefGoogle Scholar
  52. 52.
    Christodoulou DK, Tsianos EV (2000) Anemia in inflammatory bowel disease — the role of recombinant human erythropoietin. Eur J Intern Med 11: 222227Google Scholar
  53. 53.
    Cleeland CS, Demetri GD, Glaspy J, Cella DF, Portonoy RK, Cremiex PY, Itri L (1999) Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 18: 574a (abstract)Google Scholar
  54. 54.
    Cook JD (1982) Clinical evaluation of iron deficiency. Semin Hematol 19: 6–18PubMedGoogle Scholar
  55. 55.
    Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB (1999) Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 16: 459–472Google Scholar
  56. 56.
    Cullen P, Soffker J, Hopfl M, Bremer C, Schlaghecken R, Mehrens T, Assmann G, Schaefer RM (1999) Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant 14: 659–665PubMedCrossRefGoogle Scholar
  57. 57.
    Cullis JO, Duncombe AS, Dudley JM, Lumley HS, Apperley JF, Smith AG (1998) Acute leukaemia in Jehovah’s Witnesses. Br J Haematol 100: 664–668PubMedCrossRefGoogle Scholar
  58. 58.
    Dame C, Juul SE, Christensen RD (2001) The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 79: 228–235PubMedCrossRefGoogle Scholar
  59. 59.
    Daneryd P, Svanberg E, Korner U, Lindholm E, Sandstrom R, Brevinge H, Pettersson C, Bosaeus I, Lundholm K (1998) Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 58: 5374–5379PubMedGoogle Scholar
  60. 60.
    Davis D, Charles PJ, Potter A, Feldmann M, Maini RN, Elliott MJ (1997) Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 36: 950–956PubMedCrossRefGoogle Scholar
  61. 61.
    del Peso G, Selgas R, Bajo MA, Fernandez de Castro M, Aguilera A, Cirugeda A, Jimenez C (2000) Serum level of vascular endothelial growth factor is influenced by erythropoietin treatment in peritoneal dialysis patients. ( Grupo de Estudios Peritoneales de Madrid ). Adv Petit Dial 16: 85–89Google Scholar
  62. 62.
    Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412–3425Google Scholar
  63. 63.
    Drueke T (2001) Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16: 25–28PubMedCrossRefGoogle Scholar
  64. 64.
    Dumez H, Highley M, Guetens G, De Boeck G, Hanauske A, van Oosterom AT, Maes RA, de Bruijn EA, Harper P (2001) Erythrocytes and the transfer of anticancer drugs and metabolites: a possible relationship with therapeutic outcome. Semin Oncol 28 (Suppl 8): 24–28PubMedCrossRefGoogle Scholar
  65. 65.
    Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, Pappa M, Raptis S (1999) Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia 13: 1009–1012PubMedCrossRefGoogle Scholar
  66. 66.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73–78Google Scholar
  67. 67.
    Estrin JT, Schocket L, Kregenow R, Henry DH (1999) A retrospective review of blood transfusions in cancer patients with anemia. Oncologist 4: 318–324PubMedGoogle Scholar
  68. 68.
    Farrell FX, Juul S, Elliott C, Anderson D, Jolliffe LD (2001) Erythropoietin crosses the blood brain barrier: an analysis in a nonhuman primate model. Blood 98: 148b (Abstr 4265)Google Scholar
  69. 69.
    Farrell FX, Jolliffe LK (2001) Administration of epoetin alfa every two weeks is able to sustain target hemoglobin in a nonhuman primate alternate dosing model. Blood 98: 297a (Abstr 1253)Google Scholar
  70. 70.
    Fatouros MS, Vekinis G, Bourantas KL, Mylonakis EP, Scopelitou AS, Malamou-Mitsis VD, Kappas AM (1999) Influence of growth factors erythropoietin and granulocyte macrophage colony stimulating factor on mechanical strength and healing of colonic anastomoses in rats. Eur J Surg 165: 986992Google Scholar
  71. 71.
    Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK (1997) Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52: 217–222PubMedCrossRefGoogle Scholar
  72. 72.
    Fishbane S, Kowalski EA (2000) The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 13: 381–384PubMedCrossRefGoogle Scholar
  73. 73.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1996) The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 28: 53–61PubMedCrossRefGoogle Scholar
  74. 74.
    Ford P, Henry D, Mason B (1998) Iron status in anemic cancer patients. Proc Am Soc Clin Oncol 17: 58a (Abstr 224)Google Scholar
  75. 75.
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875–2882PubMedGoogle Scholar
  76. 76.
    Gagic K, Campagnaro E, LaBorde CJ, Edavettal M, Levine EA, Potter BJ, Racey Burns LA, Burns AH (1997) The effect of clenbuterol and recombinant erythropoietin on tumor growth and the anemia caused by the Walker 256 carcinosarcoma. Life Sci 61: 2475–2484PubMedCrossRefGoogle Scholar
  77. 77.
    Gasche C, Dejaco C, Reinisch W, Tillinger W, Waldhoer T, Fueger GF, Lochs H, Gangl A (1999) Sequential treatment of anemia in ulcerative,colitis with intravenous iron and erythropoietin. Digestion 60: 262–267PubMedCrossRefGoogle Scholar
  78. 78.
    Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C (1995) Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10: 44–47PubMedGoogle Scholar
  79. 79.
    Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F (2000) Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol 13: 444–449PubMedGoogle Scholar
  80. 80.
    Gibbs MA (2000) Ascorbic acid use in hyporesponders to Epoetin alfa. Nephrol Nurs J 27: 413–415PubMedGoogle Scholar
  81. 81.
    Glaser CM, Millesi W, Kornek GV, Lang S, Schuh B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705–715PubMedCrossRefGoogle Scholar
  82. 82.
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218–1234Google Scholar
  83. 83.
    Glimelius B, Linne T, Hoffman K, Larsson L, Svensson JH, Nasman P, Svensson B, Helmers C (1998) Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16: 434–440PubMedGoogle Scholar
  84. 84.
    Goodnough LT, Marcus RE (1998) Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 75: 128–133PubMedCrossRefGoogle Scholar
  85. 85.
    Goodnough LT, Skikne B, Brugnara C (2000) Erythropoietin, iron, and erythropoiesis. Blood 96: 823–833PubMedGoogle Scholar
  86. 86.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079–2088PubMedGoogle Scholar
  87. 87.
    Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB (1990) Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38: 12–18PubMedCrossRefGoogle Scholar
  88. 88.
    Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528–1536PubMedCrossRefGoogle Scholar
  89. 89.
    Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50: 702–712PubMedCrossRefGoogle Scholar
  90. 90.
    Hamblin T (1992) Clinical features of MDS. Leuk Res 16: 89–93PubMedCrossRefGoogle Scholar
  91. 91.
    Hast R, Wallvik J, Folin A, Bernell P, Stenke L (2001) Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res 25: 13–18PubMedCrossRefGoogle Scholar
  92. 92.
    Hazard JT, Drysdale JW (1977) Ferritinaemia in cancer. Nature 265: 755756Google Scholar
  93. 93.
    Hebert LA, Birmingham DJ, Dillon JJ, Cosio FG, Shen XP (1994) Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1 (CD35). J Am Soc Nephrol 4: 1786–1791PubMedGoogle Scholar
  94. 94.
    Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandez-Richter T, Mempel W, Beck KG, Schildberg FW, Messmer K (1996) Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery 119: 523–527Google Scholar
  95. 95.
    Hellström-Lindberg E (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89: 67–71PubMedGoogle Scholar
  96. 96.
    Hellström-Lindberg E, Ahigren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, ()berg G, Österborg A, Öst A (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92: 68–75Google Scholar
  97. 97.
    Hellström-Lindberg E, Ahlgren T, Dahl I, et al (2000a) A final decision model for treating the anemia of myelodysplastic syndromes (MDS) with EPO + GCSF. Blood 96: 546a (Abstr 2347)Google Scholar
  98. 98.
    Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99: 344–351PubMedCrossRefGoogle Scholar
  99. 99.
    Hellström-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B (2001) Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 112: 714–726PubMedCrossRefGoogle Scholar
  100. 100.
    Hellström-Lindberg E, Willman C, Barrett AJ, Saunthararajah Y (2000b) Achievements in Understanding and Treatment of Myelodysplastic Syndromes. In: Hematology (Am Soc Hematol Educ Program) 110–132Google Scholar
  101. 101.
    Henry D, Abels R, Larholt K (1995) Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-alpha) therapy in cancer patients. Blood 85: 1676–1678PubMedGoogle Scholar
  102. 102.
    Henry D, George M, Kilcoyne S, Stavely N (2001) Most efficient timing of EPO dosing in breast cancer patients receiving adjuvant cyclophosphamide and doxorubicin as measured by RDW. Blood 98: 149b (Abstr 4268)Google Scholar
  103. 103.
    Henry D, Mason B, Staddon A, et al (1998) Efficacy of infed plus recombinant human erythropoietin (RHUEPO) in treating anemia in cancer patients with suboptimal response to RHUEPO: a pilot study. Proc Am Soc Clin Oncol 17: 59aGoogle Scholar
  104. 104.
    Henry DH (1998) Supplemental iron: A key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 3: 275–278PubMedGoogle Scholar
  105. 105.
    Horina JH, Petritsch W, Schmid CR, Reicht G, Wenzl H, Silly H, Krejs GJ (1993a) Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: results in three patients. Gastroenterology 104: 1828–1831PubMedGoogle Scholar
  106. 106.
    Horina JH, Schwaberger G, Brussee H, Sauseng-Fellegger G, Holzer H, Krejs GJ (1993b) Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 8: 12191222Google Scholar
  107. 107.
    Hudson JQ, Comstock TJ (2001) Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther 23: 1637–1671PubMedCrossRefGoogle Scholar
  108. 108.
    Huraib S, Abu-Aisha H, al-Momen A, al-Wakeel J, Memon N, al-Tuwaijri A (1997) Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients. Am J Kidney Dis 29: 866–870PubMedCrossRefGoogle Scholar
  109. 109.
    Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103: 1070–1074CrossRefGoogle Scholar
  110. 110.
    Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72: 449–489PubMedGoogle Scholar
  111. 111.
    Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Kroon D, Freedy J, Zivin RA, Mulcahy LS, Jolliffe LK (1997) Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 4: 939–950PubMedCrossRefGoogle Scholar
  112. 112.
    Juul SE, Anderson DK, Li Y, Christensen RD (1998) Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 43: 40 X19Google Scholar
  113. 113.
    Juul SE, Ledbetter DJ, Joyce AE, Dame C, Christensen RD, Zhao Y, DeMarco V (2001) Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 49: 182–189PubMedCrossRefGoogle Scholar
  114. 114.
    Kaito K, Kobayashi M, Sakamoto M, Shimada T, Masuoka H, Nishiwaki K, Saeki A, Sekita T, Otsubo H, Hosoya T (1998) Combination chemotherapy with G-CSF, M-CSF and EPO: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs. Acta Haematol 100: 57–60PubMedCrossRefGoogle Scholar
  115. 115.
    Kaltwasser JP, Gottschalk R (1999) Erythropoietin and iron. Kidney Int Suppl 69: S49–56PubMedCrossRefGoogle Scholar
  116. 116.
    Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B (2001) Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 28: 2430–2436PubMedGoogle Scholar
  117. 117.
    Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR (1997) Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol 58: 251–256PubMedCrossRefGoogle Scholar
  118. 118.
    Kato A, Hamada M, Suzuki T, Maruyama T, Maruyama Y, Hishida A (2001a) Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis. Nephron 89: 110–112PubMedCrossRefGoogle Scholar
  119. 119.
    Kato A, Odamaki M, Takita T, Furuhashi M, Maruyama Y, Hishida A (2001b) High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 16: 1838–1844PubMedCrossRefGoogle Scholar
  120. 119a.
    Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA (1998) Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339: 578–583PubMedCrossRefGoogle Scholar
  121. 120.
    Kausz AT, Obrador GT, Pereira BJ (2000) Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 36: S39–51PubMedCrossRefGoogle Scholar
  122. 121.
    Kawakami M, Iwasaki S, Sato K, Takahashi M (2000) Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem Biophys Res Commun 279: 293–297PubMedCrossRefGoogle Scholar
  123. 122.
    Kersten MJ, Lange R, Smeets ME, Vreugdenhil G, Roozendaal KJ, Lameijer W, Goudsmit R (1996) Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 73: 247–252PubMedCrossRefGoogle Scholar
  124. 123.
    Kietz DA, Pepmueller PH, Moore TL (2001) Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 28: 360–362PubMedGoogle Scholar
  125. 124.
    Kimata H, Yoshida A, Ishioka C, Masuda S, Sasaki R, Mikawa H (1991) Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin Exp Immunol 85: 151–156PubMedCrossRefGoogle Scholar
  126. 125.
    Kitagawa S, Saito M, Miura Y (1995) Recombinant human erythropoietin at high doses stimulates thrombopoiesis: treatment for protracted severe myelosuppression complicating interferon-alpha and busulfan therapy for chronic myelogenous leukaemia. Eur J Haematol 55: 285–286PubMedCrossRefGoogle Scholar
  127. 126.
    Kobayashi T, Makuuchi H, Takahashi K, Furuse A, Shibata Y, Tsuno H, Kotsuka Y, Kubota H, Imanaka K, Tsukada T, Nakashima M (2001) Effects of recombinant human erythropoietin therapy on blood coagulation and fibrinolysis system. Ann Thorac Cardiovasc Surg 7: 273–277PubMedGoogle Scholar
  128. 127.
    Konijn AM, Hershko C (1977) Ferritin synthesis in inflammation. I. Pathogenesis of impaired iron release. Br J Haematol 37: 7–16Google Scholar
  129. 128.
    Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM (2001) A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate ( Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 16: 1239–1244Google Scholar
  130. 129.
    Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y (1999) Effects of erythropoietin on neuronal activity. J Neurochem 72: 2565–2572PubMedCrossRefGoogle Scholar
  131. 130.
    Krawczyk W, Dmoszynska A, Ledwozyw A, Marczewski K (1995a) Human erythropoietin changes fatty acids composition of blood platelet phospholipids in hemodialyzed patients. Nephron 69: 355 (Letter)Google Scholar
  132. 131.
    Krawczyk W, Dmoszynska A, Marczewski K, Ledwozyw A (1995b) Human erythropoietin improves the blood platelet phospholipid composition in chronically hemodialyzed patients. Exp Nephrol 3: 265–266PubMedGoogle Scholar
  133. 132.
    Kristal B, Shurtz-Swirski R, Shasha SM, Manaster J, Shapiro G, Furmanov M, Hassan K, Weissman I, Sela S (1999) Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients. Nephron 81: 406–413PubMedCrossRefGoogle Scholar
  134. 133.
    Kuriyama S, Hopp L, Yoshida H, Hikita M, Tomonari H, Hashimoto T, Sakai O (1996) Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 9: 426–431PubMedCrossRefGoogle Scholar
  135. 134.
    Lipschitz DA, Bothwell TH, Seftel HC, Wapnick AA, Charlton RW (1971) The role of ascorbic acid in the metabolism of storage iron. Br J Haematol 20: 155–163PubMedCrossRefGoogle Scholar
  136. 135.
    Lissoni P, Rovelli F, Baiocco N, Tangini G, Fumagalli L (2001) A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res 21: 777–779PubMedGoogle Scholar
  137. 136.
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874PubMedGoogle Scholar
  138. 137.
    Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H (2000) Oxidation parameters in complete correction of renal anemia. Clin Nephrol 53: S30–35PubMedGoogle Scholar
  139. 138.
    Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693–1699PubMedCrossRefGoogle Scholar
  140. 139.
    Ludwig H, Fritz E, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, Umek H (1993) Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 4: 161–167PubMedGoogle Scholar
  141. 140.
    Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84: 1056–1063PubMedGoogle Scholar
  142. 141.
    Macdougall IC (1999) Strategies for iron supplementation: oral versus intravenous. Kidney Int Supp169: 561–66Google Scholar
  143. 142.
    Macdougall IC (2000) Novel erythropoiesis stimulating protein. Semin Nephrol 20: 375–381PubMedGoogle Scholar
  144. 143.
    Macdougall IC, Chandler G, Elston O, Harchowal J (1999a) Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 34: 540–46CrossRefGoogle Scholar
  145. 144.
    Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J (1999b) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 23922395Google Scholar
  146. 145.
    Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE (1996) A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694–1699PubMedCrossRefGoogle Scholar
  147. 146.
    Maeda Y, Sakaguchi M, Naiki Y, Sumimoto Y, Miyatake JI, Matsuda M, Hasegawa H, Kanamaru A (2001) Possible involvement of soluble erythropoietin receptor in resistance to erythropoietin in patients with renal anemia. Am J Nephrol 21: 426PubMedCrossRefGoogle Scholar
  148. 147.
    Maione D, Wiznerowicz M, Delmastro P, Cortese R, Ciliberto G, La Monica N, Savino R (2000) Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 11: 859–868PubMedCrossRefGoogle Scholar
  149. 148.
    Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, Mysliwiec M, Buczko W (1995) A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 77: 133–143PubMedCrossRefGoogle Scholar
  150. 149.
    Mantovani G, Ghiani M, Curreli L, Maccio A, Massa D, Succu G, Lai P, Massa E, Mudu MC, Astara G (1999) Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients. Oncol Rep 6: 421426Google Scholar
  151. 150.
    Mantovani L, Lentini G, Hentschel B, Wickramanayake PD, Loeffler M, Diehl V, Tesch H (2000) Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 109: 367–375PubMedCrossRefGoogle Scholar
  152. 151.
    Marti HH, Bernaudin M, Petit E, Bauer C (2000) Neuroprotection and angiogenesis: Dual role of erythropoietin in brain ischemia. News Physiol Sci 15: 225–229Google Scholar
  153. 152.
    Marti HH, Gassmann M, Wenger RH, Kvietikova I, Morganti-Kossmann MC, Kossmann T, Trentz O, Bauer C (1997) Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 51: 416418Google Scholar
  154. 153.
    McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr. (2001). Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis 37: E36PubMedCrossRefGoogle Scholar
  155. 154.
    Melendez O (2000) Intravenous vitamin C for erythropoietin resistance. Semin Dial 13: 335–336PubMedCrossRefGoogle Scholar
  156. 155.
    Miller AM, Noyes WE, Taetle R, List AF (1999) Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome. Leuk Res 23: 77–83PubMedCrossRefGoogle Scholar
  157. 156.
    Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N (2001) Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 98: 5181–5186PubMedCrossRefGoogle Scholar
  158. 157.
    Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A (1997) Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 98: 204–210PubMedCrossRefGoogle Scholar
  159. 158.
    Miyazaki Y, Kuriyama K, Higuchi M, Tsushima H, Sohda H, Imai N, Saito M, Kondo T, Tomonaga M (1997) Establishment and characterization of a new erythropoietin-dependent acute myeloid leukemia cell line, AS-E2. Leukemia 11: 1941–1949PubMedCrossRefGoogle Scholar
  160. 159.
    Moore IM, Espy KA, Kaufmann P, Kramer J, Kaemingk K, Miketova P, Mollova N, Kaspar M, Pasvogel A, Schram K, Wara W, Hutter J, Matthay K (2000) Cognitive consequences and central nervous system injury following treatment for childhood leukemia. Semin Oncol Nurs 16: 279–290; discussion 291–279Google Scholar
  161. 160.
    Moore RD (1999) Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 29: 44–49PubMedCrossRefGoogle Scholar
  162. 161.
    Morere JF, Bouillet T, Piperno-Neumann S, Tourani JM, Brunet A, Hennebelle F, Bareau JL (1997) [Treatment of advanced kidney cancer using recombinant erythropoietin]. Prog Urol 7: 399–402Google Scholar
  163. 162.
    Morlock M, Kissel T, Li YX, Koll H, Winter G (1998) Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in-vitro release properties. J Control Release 56: 105–115PubMedCrossRefGoogle Scholar
  164. 163.
    Motoji T, Hoshino S, Ueda M, Takanashi M, Masuda M, Nakayama K, Oshimi K, Mizoguchi H (1990) Enhanced growth of clonogenic cells from acute myeloblastic leukaemia by erythropoietin. Br J Haematol 75: 60–67PubMedCrossRefGoogle Scholar
  165. 164.
    Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87: 4076–4081PubMedGoogle Scholar
  166. 165.
    Nissenson AR (1997) Achieving target hematocrit in dialysis patients: new concepts in iron management. Am J Kidney Dis 30: 907–911PubMedCrossRefGoogle Scholar
  167. 166.
    Nowrousian MR, Kasper C, Oberhoff C, Essers U, Voigtmann R, Gallasch W, Quarder 0 (1996) Pathophysiology of cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds) rhErythropoietin in Cancer Supportive Treatment. Marcel Dekker, New York, Basel, Hong Kong, pp 13–34Google Scholar
  168. 167.
    Nowrousian MR (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15 Suppl 1: S19–28Google Scholar
  169. 168.
    Oberhoff C, Krumreich B, Petry KU, Rebmann U, Nowrousian MR, Kasper C, Voigtmann R, Karthaus M, Merkle E, Gallaasch W, Quarder O, Schindler AE (2000) Effekt von rekombinantem humanen Erythropoetin auf den Transfusionsbedarf and die Hämoglobinkonzentration bei Patienten mit soliden Tumoren and chemotherapieinduzierter Anämie. Tumordiagn u Ther 21: 15–25CrossRefGoogle Scholar
  170. 169.
    Obermair A, Cheuk R, Horwood K, Janda M, Bachtiary B, Schwanzelberger B, Stoiber A, Nicklin JL, Perrin LC, Crandon AJ (2001) Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 92: 903–908PubMedCrossRefGoogle Scholar
  171. 170.
    Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, Noguchi CT (2000) Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275: 39754–39761PubMedCrossRefGoogle Scholar
  172. 171.
    Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin ( Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 87: 2675–2682Google Scholar
  173. 172.
    Paczek L, Schaefer RM, Heidland A (1990) Improved function of B lymphocytes in dialysis patients treated by recombinant human erythropoietin. Contrib Nephrol 87: 36–41PubMedGoogle Scholar
  174. 173.
    Pecorelli S. (2000). Suboptimal hemoglobin levels: do they impact patients and their therapy? Introduction. Semin Oncol 27 (Suppl 4): 1–3PubMedGoogle Scholar
  175. 174.
    Pfaffl W, Gross HJ, Neumeier D, Nattermann U, Samtleben W, Gurland HJ (1988) Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin. Contrib Nephrol 66: 195–204PubMedGoogle Scholar
  176. 175.
    Pierelli L, Perillo A, Greggi S, Salerno G, Panici PB, Menichella G, Fattorossi A, Leone G, Mancuso S, Scambia G (1999a) Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 17: 1288–1295PubMedGoogle Scholar
  177. 176.
    Pierelli L, Scambia G, Bonanno G, Coscarella A, De Santis R, Mole A, Battaglia A, Fattorossi A, Romeo V, Menichella G, Mancuso S, Leone G (1999b) Expansion of granulocyte colony-stimulating factor/chemotherapymobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15. Exp Hematol 27: 416–424PubMedCrossRefGoogle Scholar
  178. 177.
    Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ (1991) Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9: 2021–2026PubMedGoogle Scholar
  179. 178.
    Ponka A, Kuhlback B (1983) Serum ascorbic acid in patients undergoing chronic hemodialysis. Acta Med Scand 213: 305–307PubMedCrossRefGoogle Scholar
  180. 179.
    Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F (2001) Epoetin alf a therapy increases hemoglo-bin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19: 4126–4134PubMedGoogle Scholar
  181. 180.
    Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY (1999) Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Onco117: 2840–2846Google Scholar
  182. 181.
    Regulier E, Schneider BL, Deglon N, Beuzard Y, Aebischer P (1998) Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther 5: 1014–1022PubMedCrossRefGoogle Scholar
  183. 182.
    Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, Fernandez Fuertes I, Gonzalez FA, Font L, Junca J, del Arco A, Malcorra JJ, 1 Equiza EP, de Mendiguren BP, Romero M (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 84: 1058–1064Google Scholar
  184. 183.
    Rinsch C, Regulier E, Deglon N, Dalle B, Beuzard Y, Aebischer P (1997) A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 8: 1881–1889PubMedCrossRefGoogle Scholar
  185. 184.
    Roger SD, Piper J, Tucker B, Raine AE, Baker LR, Kovacs IB (1993) Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients. Nephrol Dial Transplant 8: 213–217PubMedGoogle Scholar
  186. 185.
    Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia ( MDS ). Br J Haematol 89: 831–837Google Scholar
  187. 186.
    Rubins J (1995) Metastatic renal cell carcinoma: response to treatment with human recombinant erythropoietin. Ann Intern Med 122: 676–677PubMedGoogle Scholar
  188. 187.
    Russo F, Guadagni S, Mattera G, Esposito G, Abate G (1999) Combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin ( EPO) for the treatment of advanced non-responsive chronic lymphocytic leukemia. Eur J Haematol 63: 325–331Google Scholar
  189. 188.
    Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95: 4635–4640PubMedCrossRefGoogle Scholar
  190. 189.
    Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088–1094PubMedCrossRefGoogle Scholar
  191. 190.
    Schaefer RM, Schaefer L (1999) Hypochromic red blood cells and reticulocytes. Kidney Int Suppl 69: S44–48PubMedCrossRefGoogle Scholar
  192. 191.
    Schmidt-Mende J, Tehranchi R, Forsblom AM, Joseph B, Christensson B, Fadeel B, Zhivotovsky B, Hellstrom-Lindberg E (2001) Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 15: 742–751PubMedCrossRefGoogle Scholar
  193. 192.
    Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche C, Lochs H, Raedler A (1996) Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 334: 619–623PubMedCrossRefGoogle Scholar
  194. 193.
    Schrijvers D, Highley M, De Bruyn E, Van Oosterom AT, Vermorken JB (1999) Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 10: 147–153PubMedCrossRefGoogle Scholar
  195. 194.
    Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, Gordon MS, Lichtin AE, Wade JL, 3rd, Woolf S, Aronson N (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204–1214PubMedCrossRefGoogle Scholar
  196. 195.
    Sela S, Shurtz-Swirski R, Sharon R, Manaster J, Chezar J, Shkolnik G, Shapiro G, Shasha SM, Merchav S, Kristal B (2001) The polymorphonuclear leukocyte—a new target for erythropoietin. Nephron 88: 205–210PubMedCrossRefGoogle Scholar
  197. 196.
    Sennesael JJ, Van der Niepen P, Verbeelen DL (1991) Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 40: 121–128PubMedCrossRefGoogle Scholar
  198. 197.
    Serguera C, Bohl D, Rolland E, Prevost P, Heard JM (1999) Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells. Hum Gene Ther 10: 375–383PubMedCrossRefGoogle Scholar
  199. 198.
    Shasha D, George MJ, Harrison LB (2000) Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Blood 96: 434aGoogle Scholar
  200. 199.
    Shurtz-Swirski R, Kristal B, Shkolnik T, Weissman I, Shapiro G, Shasha SM (1996) Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients. Nephron 72: 27–29PubMedCrossRefGoogle Scholar
  201. 200.
    Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP, Dimopoulou MN, Kyrtsonis MC, Tsaftaridis P, Kontopidou FN, Pangalis GA (2001) “Down-staging” Rai stage IIIB-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Blood 98: 634a (Abstr 2656)Google Scholar
  202. 201.
    Sigounas G, Salleng K, Mehlhop P, Sallah S, Collins M, Kardatos A, Sigounas D (2001) Erythropoietin inhibits drug-induced fibrosis and improves pulmonary function. Blood 98: 798a (Abstr 3321)Google Scholar
  203. 202.
    Silver DF, Piver MS (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol 73: 280–284Google Scholar
  204. 203.
    Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, laina A (2001) The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 55: 212–219PubMedGoogle Scholar
  205. 204.
    Singh AB, Singh M, Palekar S, Levy S, Nunn C, Mann RA (1992) The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients. J Med 23: 289–302PubMedGoogle Scholar
  206. 205.
    Siren AL, Ehrenreich H (2001) Erythropoietin — a novel concept for neuro-protection. Eur Arch Psychiatry Clin Neurosci 251: 179–184PubMedCrossRefGoogle Scholar
  207. 206.
    Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98: 4044–4049PubMedCrossRefGoogle Scholar
  208. 207.
    Smibert E, Anderson V, Godber T, Ekert H (1996) Risk factors for intellectual and educational sequelae of cranial irradiation in childhood acute lymphoblastic leukaemia. Br J Cancer 73: 825–830PubMedCrossRefGoogle Scholar
  209. 208.
    Sommerburg O, Grune T, Hampl H, Riedel E, Ehrich JH, Siems WG (2000) Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients? Clin Nephrol 53: S23–29PubMedGoogle Scholar
  210. 209.
    Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, et al. (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232: 61–65PubMedCrossRefGoogle Scholar
  211. 210.
    Stasi R, Brunetti M, Bussa S, Conforti M, Di Giulio C, Crescenzi A, Terzoli E, Vecchione A, Pagano A (1997) Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 3: 733739Google Scholar
  212. 211.
    Stasi R, Pagano A, Terzoli E, Amadori S (1999) Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol 105: 141–148PubMedCrossRefGoogle Scholar
  213. 212.
    Stockenhuber F, Kurz RW, Geissler K, Jahn C, Hinterberger W, Balcke P, Lechner K (1990) Recombinant human erythropoietin activates a broad spectrum of progenitor cells. Kidney Int 37: 150–156PubMedCrossRefGoogle Scholar
  214. 213.
    Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B (2000) Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95: 2983–2989PubMedGoogle Scholar
  215. 214.
    Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100: 79–89PubMedCrossRefGoogle Scholar
  216. 215.
    Tang WW, Stead RA, Goodkin DA (1998) Effects of Epoetin alfa on hemostasis in chronic renal failure. Am J Nephrol 18: 263–273PubMedCrossRefGoogle Scholar
  217. 216.
    Tarng DC, Huang TP (1998) A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 13: 28672872Google Scholar
  218. 217.
    Tarng DC, Huang TP, Wei YH (2001) Erythropoietin and iron: the role of ascorbic acid. Nephrol Dial Transplant 16: 35–39PubMedCrossRefGoogle Scholar
  219. 218.
    Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC (1999) Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 55: 2477–2486PubMedCrossRefGoogle Scholar
  220. 219.
    Teicher BA, Holden SA, al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50: 3339–3344PubMedGoogle Scholar
  221. 220.
    Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G (2001) The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16: 14161423Google Scholar
  222. 221.
    Thews O, Kelleher DK, Vaupel P (2001). Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61: 1358–1361PubMedGoogle Scholar
  223. 222.
    Thomas G (2001) The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 28 (Suppl 8): 60–65PubMedCrossRefGoogle Scholar
  224. 223.
    Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, Rose EH, Dugan MH (2000) Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 95: 1175–1179Google Scholar
  225. 224.
    Tsukuda M, Mochimatsu I, Nagahara T, Kokatsu T, Sawaki S, Kubota A, Furkawa M, Arai Y (1993) Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother 36: 52–56PubMedCrossRefGoogle Scholar
  226. 225.
    Turner R, Anglin P, Burkes R, Couture F, Evans W, Goss G, Grimshaw R, Melosky B, Paterson A, Quirt I (2001) Epoetin alfa in cancer patients: evidence-based guidelines. J Pain Symptom Manage 22: 954–965PubMedCrossRefGoogle Scholar
  227. 226.
    Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998) Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25 (Suppl 1): 39–47PubMedGoogle Scholar
  228. 227.
    Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N (2000) Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 36: 88–97Google Scholar
  229. 228.
    Vaziri ND (2000) Vascular effects of erythropoietin and anemia correction. Semin Nephrol 20: 356–363PubMedGoogle Scholar
  230. 229.
    Vaziri ND, Ateshkadi A (1999) Effects of epoetin on vascular biology. Nephrol Dial Transplant 14: 46–49PubMedCrossRefGoogle Scholar
  231. 230.
    Vogel S (2000) Benefits of early utilization of intravenous iron. Nephrol Nurs J 27: 61–65PubMedGoogle Scholar
  232. 231.
    Volberding P (2000) Consensus statement: anemia in HIV infection—current trends, treatment options, and practice strategies. Anemia in HIV Working Group. Clin Ther 22: 1004–1020; discussion 1003Google Scholar
  233. 232.
    Waber DP, Carpentieri SC, Klar N, Silverman LB, Schwenn M, Hurwitz CA, Mullenix PJ, Tarbell NJ, Sallan SE (2000) Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 22: 206–213PubMedCrossRefGoogle Scholar
  234. 233.
    Wagner W, Hermann R, Hartlapp J, Esser E, Christoph B, Muller MK, Krech R, Koch 0 (2000) Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther Onkol 176: 73–80Google Scholar
  235. 234.
    Wang AYM, Yu AWY, Lai KN, Lui SF (2000) Dosage requirement of erythropoietin can be reduced with more frequent administration. Nephrology 5: 33–38CrossRefGoogle Scholar
  236. 235.
    Waters JS, O’Brien ME, Ashley S (2002). Management of anemia in patients receiving chemotherapy. J Clin Oncol 20: 601–603PubMedGoogle Scholar
  237. 236.
    Weinberg ED (1996) The role of iron in cancer. Eur J Cancer Prey 5: 19–36Google Scholar
  238. 237.
    Weinberg ED (1999) Iron therapy and cancer. Kidney Int Suppl 69: S131–134PubMedCrossRefGoogle Scholar
  239. 492.
    M. R. Nowrousian: Current status and future developments of rhEPOGoogle Scholar
  240. 238.
    Weiss G (1999) Iron and anemia of chronic disease. Kidney Int Suppl 69: S12–17PubMedCrossRefGoogle Scholar
  241. 239.
    Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000) The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15: 2014–2019Google Scholar
  242. 240.
    Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647–657PubMedCrossRefGoogle Scholar
  243. 241.
    Zachee P (1995) Controversies in selection of epoetin dosages. Issues and answers. Drugs 49: 536–547PubMedCrossRefGoogle Scholar
  244. 242.
    Zaharia-Czeizler V (2001) Erythropoietin stops chronic diffuse transfusion-dependent gastrointestinal bleeding. Ann Intern Med 135: 933PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  1. 1.Department of Internal Medicine (Cancer Research), West German Cancer CenterUniversity of Essen Medical SchoolEssenGermany

Personalised recommendations